Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor

被引：2
|
作者：
Peterson, Danielle [1 ]
King, Brett [1 ]
机构：
[1] Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA
来源：
DERMATITIS | 2021年 / 32卷 / 1S期
关键词：
ATOPIC-DERMATITIS;
D O I：
10.1097/DER.0000000000000783
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E98 / E99
页数：2
相关论文
共 50 条
  • [41] Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
    Verstovsek, Srdan
    POSTGRADUATE MEDICINE, 2013, 125 (01) : 128 - 135
  • [42] Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis
    Gonzales, Andrea J.
    Aleo, Michelle
    Mahabir, Sean
    Messamore, James
    Stegemann, Michael
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2024, 47 (06) : 447 - 453
  • [43] The Rate of Infections With Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis
    Tarafdar, Nawar
    Sachdeva, Muskaan
    Dubale, Natnaiel M.
    Smythe, Ciaran
    Lytvyn, Yuliya
    Maliyar, Khalad
    Georgakopoulos, Jorge R.
    Mufti, Asfandyar
    Yeung, Jensen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024, 28 (01) : 83 - 85
  • [44] Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis
    De, Surya K. K.
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (38) : 4278 - 4282
  • [45] Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab
    Yang, Nali
    Chen, Lele
    Shao, Junyi
    Jiang, Fan
    Liu, Jingjing
    Li, Zhiming
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (05) : 828 - 830
  • [46] Predictors of maintenance of response in patients with moderate-to-severe atopic dermatitis after interruption of the oral Janus kinase 1-selective inhibitor abrocitinib
    Gooderham, M. J.
    Girolomoni, G.
    Moore, J. O.
    Silverberg, J. I.
    Curto, M.
    Zhang, W.
    DiBonaventura, M.
    Valdez, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E106 - E106
  • [47] The risk of infections with janus kinase inhibitor treatment for atopic dermatitis: a systematic review and meta-analysis
    Tarafdar, N.
    Sachdeva, M.
    Dubale, N.
    Smythe, C.
    Lytvyn, Y.
    Maliyar, K.
    Georgakopoulos, J.
    Mufti, A.
    Yeung, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S338 - S338
  • [48] JAAD Game Changers: Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
    Grant-Kels, Jane M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (05) : 1028 - 1028
  • [49] Topical Janus kinase inhibitors in the treatment of atopic eczema
    Doyle, M.
    ALLERGY, 2023, 78
  • [50] Atopic Dermatitis: A Guide to Transitioning to Janus Kinase Inhibitors
    Rick, Jonathan W.
    Lio, Peter
    Atluri, Swetha
    Hsiao, Jennifer L.
    Shi, Vivian Y.
    DERMATITIS, 2023, 34 (04) : 297 - 300
12345